Adjusted EBT
The Adjusted EBITDA Total for continuing operations amounted to € 607.0 million in the first three months of 2024 and was thus 3.3% lower than the prior-year value of € 627.9 million in the first three months of 2023.
In the 2024 reporting period, the non-recurring items eliminated in the Adjusted EBT came to € 19.2 million (3M 2023: € 29.7 million). The following table provides a detailed list of the non-recurring items:
Non-recurring Items
Non-recurring Items | ||||||||
in € million | 3M 2023 | 3M 2024 | Change in % | 12M 2023 | ||||
Transactions* | 13.0 | 4.3 | -66.9 | 70.0 | ||||
Personnel matters | 12.7 | 6.8 | -46.5 | 35.1 | ||||
Business model optimization | 2.2 | 6.7 | >100 | 34.9 | ||||
Research & development | 1.8 | 1.2 | -33.3 | 6.8 | ||||
Refinancing and equity measures | – | 0.2 | – | 1.1 | ||||
Total non-recurring items | 29.7 | 19.2 | -35.4 | 147.9 | ||||
- *Including one-time expenses in connection with acquisitions, such as HR measures relating to the integration process and other follow-up costs.